Amlenetug is tailored to attach to all major extracellular α-synuclein forms. The human monoclonal antibody aims to prevent ...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...

Value is just one of the five Stock Grades included in our A+ Investor service. AAII members can see the top-graded stocks—those with grades of A or B for value, growth, momentum, earnings estimate ...

MINNEAPOLIS, Feb. 19, 2025 /PRNewswire/ -- The American Academy of Neurology (AAN) has developed a new systematic review to summarize for neurologists and other clinicians the evidence for ...

Baxter has appointed Heather Knight as Executive Vice President and COO Baxter International has appointed Heather Knight, who has been leading the company’s Medical Products and Therapies unit, as ...

DUBAI, UAE, Feb. 17, 2025 /PRNewswire/ -- CanSino Biologics Inc. (CanSinoBIO or the Company), a leading Chinese vaccine innovator, has been invited to the 2025 World Government Summit in Dubai ...

Amlenetug was delivered as an intravenous infusion every four weeks. About MSA MSA is a rapidly progressing rare condition of the nervous system that causes damage to nerve cells in the brain.

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...

Lundbeck’s investigational drug, amlenetug, has been granted Fast Track Designation by the US Food and Drug Administration (FDA) as a potential treatment for multiple system atrophy (MSA). This ...